Forest Riekhof

Forest Riekhof

Auto-generated profile, based on publicly available information

Forest Riekhof

Saint Louis Veterans Affairs Medical Center, Saint Louis, MO; Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
FRForest Riekhof
Forest Riekhof
YYYan Yan
Yan Yan
CBCharles L. Bennett
Charles L. Bennett
KSKristen M. Sanfilippo
Kristen M. Sanfilippo
KCKenneth R. Carson
Kenneth R. Carson
MSMartin W Schoen
Martin W Schoen

2 July 2026 in Journal of Cardiac Failure - Intersections
Verified
Journal Article
Open access
JBJackson S. Burton
Jackson S. Burton
FRForest Riekhof
Forest Riekhof
JGJake Goldstein
Jake Goldstein
IKIoannis Kyriakoulis
Ioannis Kyriakoulis
EDElizabeth Dranow
Elizabeth Dranow
THThomas C. Hanff
Thomas C. Hanff

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SGSrinivas Govindan
Srinivas Govindan
SLSuhong Luo
Suhong Luo
NCNina Cheranda
Nina Cheranda
FRForest Riekhof
Forest Riekhof
MSMartin W Schoen
Martin W Schoen
113 Background: In metastatic castrate resistant prostate cancer (mCRPC) there is a lack of studies that explore the interaction of comorbidities on treatment outcomes, which presents a challenge in choosing the right drug. In patients with diabetes mellitus, two common therapies, enzalutamide (ENZ) and abiraterone (ABI) have different effectiveness due to different mechanisms of action and because ABI requires co-administration of prednisone. Thus, in this study, we aim to assess the survival of patients with comorbid diabetes treated with ENZ and ABI. Methods: Patients treated with AA or ENZ for mCRPC from September 10, 2014, to June 2, 2017 were identified within the Veterans Health Administration. For these patients, presence of diabetes or complicated diabetes was determined using the Charlson method from the International Classification of Diseases (ICD) 9/10 codes. A Kaplan–Meier time to event analysis and the cox proportional hazards modeling was used to analyze the data with the latter including covariates such as age, Charlson Comorbidity Index, body-mass index, treatment with bone-directed therapy, black race, and baseline PSA at start of treatment with ENZ or ABI. Results: We identified 5822 patients treated for mCRPC, of which 2202 had diabetes and were treated using either ENZ (n = 1041) or ABI (n = 1161). Median survival of patients with diabetes treated with ENZ was 3 months longer than in patients treated with ABI (23.8 vs. 20.8, p = 0.002 by log-rank). In 3620 patients without diabetes, no significant difference in median survival (24.7 vs. 22.7 months, p = 0.065) was seen between ENZ (n = 1463) and ABI (n = 2157). In a multivariable model, ENZ was associated with improved survival in patients with diabetes (adjusted HR 0.87, 95% CI 0.79-0.97) and in patients without diabetes (adjusted HR 0.90, 95% CI 0.83-0.98). Conclusions: ENZ was associated with improved 3-month median survival in patients with diabetes compared to ABI in unadjusted analyses. Additionally, in adjusted analyses the cox proportional model also showed significantly better survival in mCRPC patients treated with ENZ both with and without diabetes, although the findings are more robust for patients with diabetes. The cause of these differences is unknown, so there may be differences in efficacy and adverse events between the two agents in real-world use. Further assessment of patient outcomes with comorbid disease is appropriate to improve care of patients with advanced prostate cancer.